Neoplastic Skin Complications in Transplant Patients: Experience of an Italian Multidisciplinary Transplant UnitMarconi B#, Ricotti F#, Giannoni M, Campanati A* and Offidani A
Department of Clinical and Molecular medicine, Dermatology Unit, Polytechnic University of Marche, Italy
- *Corresponding Author:
- Dr. Campanati Anna
Department of Clinical and Molecular Sciences
Polytechnic Marche University
E-mail: [email protected]
Received date: April 29, 2015 Accepted date: June 15, 2015 Published date: June 22, 2015
Citation: Marconi B, Ricotti F, Giannoni M, Campanati A, Offidani A (2015) Neoplastic Skin Complications in Transplant Patients: Experience of an Italian Multidisciplinary Transplant Unit. J Clin Exp Dermatol Res 6:295. doi: 10.4172/2155-9554.10000295
Copyright: © 2015 Marconi B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Transplant patients need to be strictly followed, since the immunosuppressive therapies they usually receive can increase the risk of skin complications. This study aims to evaluate the prevalence of neoplastic skin complications in transplant patients. We analyzed 256 liver or kidney transplant patients. The follow-up mean period was 7 ± 3.5 years. The 18.36% of patients developed neoplastic complications, among these 9.37% actinic keratoses, 8.20% non-melanoma skin cancer, and 0.78% cutaneous melanoma. Among patients who developed non melanoma skin cancer, 61.90% had basal cell carcinoma, 23.81% squamous cell carcinoma, 52% Kaposi's sarcoma and 4.76%, Malherbe’s epithelioma. Was also evaluated the prevalence of cutaneous neoplastic complications according the immunosuppressive regimen received by patients as follows: cyclosporine, tacrolimus, steroids, mycophenolate mofetil or everolimus, in single, double or triple therapy. This study demonstrated the increased risk of skin cancer in transplant patients during the first 7 years of follow-up and made the dermatologists aware about the need of a regularcutaneous follow up for this subset of patients.